Johnson & Johnson (JNJ) Liabilities from Discontinued Operations (2023)

Johnson & Johnson's (JNJ) quarterly Liabilities from Discontinued Operations came in at 3590000000.0 in Q1 2023.

Johnson & Johnson (JNJ) Liabilities from Discontinued Operations (2023) Analysis & Trends

Johnson & Johnson has disclosed Liabilities from Discontinued Operations across 1 years of filings, most recently posting 3590000000.0 for Q1 2023.

Liabilities from Discontinued Operations for Q1 2023 came in at 3590000000.0, changed N/A year-over-year; the trailing twelve-month figure through Jan 2023 was 3590000000.0 (changed N/A YoY), and the FY2023 annual result was 3590000000.0, changed N/A from the prior year.
Liabilities from Discontinued Operations came in at 3590000000.0 for Q1 2023 at Johnson & Johnson.
In the past five years, Liabilities from Discontinued Operations ranged from a high of 3590000000.0 in Q1 2023 to a low of 3590000000.0 in Q1 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Gsk	92,316,836.42 Bn	92,316,831.46 Bn	7.76 Bn
2	Eli Lilly	983.57 Bn	978.29 Bn	16.22 Bn
3	Johnson & Johnson	553.56 Bn	531.50 Bn	15.96 Bn
4	AbbVie	383.35 Bn	374.00 Bn	10.78 Bn
5	Merck	281.71 Bn	276.06 Bn	12.09 Bn
6	Amgen	182.20 Bn	170.16 Bn	5.87 Bn
7	Gilead Sciences	153.71 Bn	145.98 Bn	5.52 Bn
8	Pfizer	143.75 Bn	130.98 Bn	-1.21 Bn
9	Bristol Myers Squibb	109.71 Bn	99.25 Bn	8.07 Bn
10	Novartis Ag	108.28 Bn	107.60 Bn	-

Download Data

Date	Value
Jan 1, 2023	3.59 Bn
Jan 1, 2023	3.59 Bn